Neuroblastomas Turkish Society for Radiation Oncology Pediatric Tumors Study Group OBJECTIVES In this multicentric retrospective analysis we evaluated the oncologic outcome of patients with ID: 931475
Download Presentation The PPT/PDF document "The Results of Radiotherapy in Childhood" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
The Results of Radiotherapy in Childhood
Neuroblastomas
: Turkish Society for Radiation Oncology- Pediatric Tumors Study Group
OBJECTIVES:
In
this multicentric retrospective analysis, we evaluated the oncologic outcome of patients with neuroblastoma (NBL) who were treated with radiotherapy (RT) in addition to systemic chemotherapy and surgery.
Melis Gültekin1, Gizem Coşgun2, Ayşe Nur Demiral3, Zeynep Ağmaç4, Cem Uzal5, Melek Tuğçe Yılmaz1, Yavuz Anacak2, Fulya Ağaoğlu4, Nur Olgun6, Serap Aksoylar7, Canan Akyüz8, Murat Gürkaynak1, Ferah Yıldız1, Serra Kamer21Hacettepe University Faculty of Medicine, Department of Radiation Oncology, 2Ege University Faculty of Medicine, , Department of Radiation Oncology, 3Dokuz Eylul University Faculty of Medicine, Department of Radiation Oncology, 4Acıbadem Mehmet Aydinlar University Faculty of Medicine, Department of Radiation Oncology, 5Trakya University Faculty of Medicine, Department of Radiation Oncology, 6Dokuz Eylul University Faculty of Medicine, Department of Pediatric Oncology, 7Ege University Faculty of Medicine, Department of Pediatric Oncology, 8Hacettepe University Faculty of Medicine, Department of Pediatric Oncology
MATERIALS AND METHODS:
Serra Kamer, MD
Ege
University Faculty of Medicine, Department of Radiation Oncology serra.kamer@ege.edu.tr
116 patients
05/2004 - 01/2018
Turkish
Pediatric Oncology Group (TPOG) 2003 (21%) and 2009 (75%) protocolGTV 30Gy, CTV 25.5 Gy
110 (95%) primary
tumor bed and lymphatic region 6 (5%) + metastatic foci
RESULTS
: Median age: 42 mos (range, 5-156 mos)41% female and 59% maleMedian LDH level: 900 U/LIR group: n=14 (12%)HR group: n=102 (88%) Metastatic disease: n=75 (65%)Median follow-up: 38 mos (range, 4-174 mos)Forty-two patients (36%) were alive without disease, 19 patients (16%) were alive with disease, and 31 (27%) patients died due to progression. Two (2%) cases had isolated local recurrence, 1 (1%) had regional recurrence, 6 (5%) were with local-regional recurrence, and 26 (22%) were with distant metastases. The 2- and 5-year overall survival (OS) rates were 86% and 69%, and the progression-free survival (PFS) rates were 64% and 53%, respectively. The LDH level (1500 vs. ≥1500 U/L) and the presence of metastasis at diagnosis were found to be significant prognostic factors for OS and PFS. Grade 3 hematological toxicity developed in 4 (3%) cases during RT. In the long-term follow-up, 7 (6%) patients had hypoplasia/atrophy on the same kidney.
CONCLUSION
S: Multidisciplinary intensive treatment should have applied in the treatment of NBL, especially in the cases of HR disease. RT provides effective local control in the primary tumor site. Long-term follow-up is necessary to evaluate treatment-related complications.